NCT03578640View on ClinicalTrials.gov

Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Elbasvir, Grazoprevir 50-100Mg Oral Tablet

Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.

Trial Locations (1)

11525

King Fahad Medical City, Riyadh

All Listed Sponsors
lead

King Fahad Medical City

OTHER_GOV

NCT03578640 - Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4 | Biotech Hunter | Biotech Hunter